New hope for advanced breast cancer: fluzoparib maintenance after platinum success
NCT ID NCT07321015
First seen Jan 10, 2026 · Last updated May 22, 2026 · Updated 21 times
Summary
This study tests a drug called fluzoparib as a maintenance treatment for people with advanced triple-negative breast cancer (TNBC) whose disease was controlled by platinum-based chemotherapy. The goal is to see if fluzoparib can delay cancer growth. The study includes patients with or without BRCA gene mutations. About 72 participants will take fluzoparib pills daily until their cancer worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.